AI Analyst Summary
Regeneron's bull thesis rests on Dupixent's continued blockbuster trajectory, which is driving 16.7% revenue growth and supporting a compelling forward P/E of just 13.4x — well below the biotech sector median. A rich pipeline across oncology and ophthalmology provides a durable growth runway beyond the core franchise. The primary risk is near-term EPS compression (-4.5% YoY) from heavy R&D spending, which could delay multiple expansion if pipeline readouts disappoint.
Fundamentals
Pe
Trailing P/E 19.9x / Forward P/E 13.4x · 4.0/5
Trailing P/E of 19.9x is modest for a large-cap biotech, and the forward P/E of 13.4x signals meaningful earnings expansion ahead. Both metrics are comfortably below the sector median, suggesting the market is not pricing in full growth potential.
Peg
PEG 1.36 · 3.0/5
A PEG of 1.36 is in neutral territory — not a compelling value signal but not stretched either. It reflects the near-term earnings dip offsetting strong revenue momentum, warranting a middle-of-road score.
Analyst Rating
Buy consensus (1.8) · 4.0/5
With 18 Buys and 9 Holds across 27 analysts and zero Sell ratings, the consensus is constructively bullish. A consensus rating of 1.8 maps to a score of 4, reflecting broad institutional conviction in the pipeline and commercial outlook.
Earnings Trend
EPS Growth -4.5% YoY; Revenue Growth +16.7% YoY · 3.0/5
Revenue is growing robustly at 16.7%, driven by Dupixent and other commercial assets, but EPS is down 4.5% YoY, likely due to elevated R&D investment and cost scaling. The divergence between top-line strength and bottom-line softness warrants a neutral score pending earnings re-acceleration.
Price Target Beat
4 of 4 quarters beat (last 4 quarters) · 4.0/5
A perfect 4-for-4 EPS beat rate over the most recent four quarters is a strong execution signal. Scored 4 rather than 5 due to limited 8-quarter history provided; full history would be needed to confirm sustained outperformance.
Management
Consistent execution with strong revenue growth · 4.0/5
Management demonstrates strong commercial execution — consistent EPS beats, 16.7% revenue growth, and zero analyst sell ratings reflect high institutional confidence. The near-term EPS dip appears tied to deliberate R&D reinvestment rather than operational deterioration, a constructive capital allocation signal.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.